J
Jean-Pierre Grünfeld
Researcher at Paris Descartes University
Publications - 31
Citations - 1814
Jean-Pierre Grünfeld is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 15, co-authored 31 publications receiving 1631 citations. Previous affiliations of Jean-Pierre Grünfeld include University of Paris-Sud & University of Paris.
Papers
More filters
Journal ArticleDOI
Lithium nephrotoxicity revisited
TL;DR: Clinical and clinical evidence demonstrates the efficacy of the ENaC inhibitor amiloride for the treatment of lithium-induced NDI; however, whether this agent can prevent the long-term adverse effects of lithium is not yet known.
Journal ArticleDOI
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
Oliver Gross,Christoph Licht,Hans J. Anders,Bernd Hoppe,Bodo B. Beck,Burkhard Tönshoff,Britta Höcker,Simone Wygoda,Jochen H. H. Ehrich,Lars Pape,Martin Konrad,Wolfgang Rascher,Jörg Dötsch,Dirk E. Müller-Wiefel,Peter F. Hoyer,Bertrand Knebelmann,Yves Pirson,Jean-Pierre Grünfeld,Patrick Niaudet,Pierre Cochat,Laurence Heidet,Said Lebbah,Roser Torra,Tim Friede,Katharina Lange,Gerhard A. Müller,Manfred Weber +26 more
TL;DR: Alport syndrome is treatable with angiotensin-converting enzyme inhibition to delay renal failure and therapy improves life expectancy in a time-dependent manner and supports the need for early diagnosis and early nephroprotective therapy in oligosymptomatic patients.
Journal ArticleDOI
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
T. Hannedouche,P. Landais,B. Goldfarb,N. El Esper,A. Fournier,Michel Godin,D. Durand,J. Chanard,F. Mignon,J.-M. Suc,Jean-Pierre Grünfeld +10 more
TL;DR: In hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with β blockers, and this effect was probably not mediated through controlling blood pressure.
Journal ArticleDOI
Lithium-induced nephropathy: Rate of progression and prognostic factors.
Claire Presne,Fadi Fakhouri,Laure-Hélène Noël,Bénédicte Stengel,C. Even,Henri Kreis,Françoise Mignon,Jean-Pierre Grünfeld +7 more
TL;DR: Lithium-induced chronic renal disease is slowly progressive and its rate of progression is related to the duration of lithium administration, which represents 0.22% of all causes of ESRD in France.
Journal ArticleDOI
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Agnes B. Fogo,Leif Bostad,Einar Svarstad,William J. Cook,Solange Moll,Federic Barbey,Laurette Geldenhuys,Michael West,Dušan Ferluga,Bojan Vujkovac,Alexander J. Howie,Aine Burns,Roy Reeve,Stephen Waldek,Laure-Hélène Noël,Jean-Pierre Grünfeld,Carmen Valbuena,João Paulo Oliveira,Justus Müller,Frank Breunig,Xiao Zhang,David G. Warnock +21 more
TL;DR: The development of a standardized scoring system of both disease-specific lesions, i.e. lipid deposition related, and general lesions of progression, showed a spectrum of histologic appearances even in early clinical stage of Fabry nephropathy.